EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2

Han Wee Ong iD, Xuan Yang, Jeffery L Smith iD, Sharon Taft-Benz, Stefanie Howell, Rebekah J Dickmander, Tammy M Havener, Marcia K Sanders, Jason W Brown, Rafael M Couñago iD, Edcon Chang iD, Andreas Krämer iD und 5 weitere

Molecules · 2024

DOI: 10.3390/molecules29174158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Han Wee Ong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, NC 27599, USA. Hauptthemen laut MEDLINE: Casein Kinase II, Protein Kinase Inhibitors, Antiviral Agents, Halogenation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense ALSRP award, Rapidly Emerging Antiviral Drug Development Initiative (READDI), NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The host kinase casein kinase 2 (CSNK2) has been proposed to be an antiviral target against β-coronaviral infection. To pharmacologically validate CSNK2 as a drug target in vivo, potent and selective CSNK2 inhibitors with good pharmacokinetic properties are required. Inhibitors based on the pyrazolo[1,5-a]pyrimidine scaffold possess outstanding potency and selectivity for CSNK2, but bioavailability and metabolic stability are often challenging. By strategically installing a fluorine atom on an electron-rich phenyl ring of a previously characterized inhibitor 1, we discovered compound 2 as a promising lead compound with improved in vivo metabolic stability. Compound 2 maintained excellent cellular potency against CSNK2, submicromolar antiviral potency, and favorable solubility, and was remarkably selective for CSNK2 when screened against 192 kinases across the human kinome. We additionally present a co-crystal structure to support its on-target binding mode. In vivo, compound 2 was orally bioavailable, and demonstrated modest and transient inhibition of CSNK2, although antiviral activity was not observed, possibly attributed to its lack of prolonged CSNK2 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Casein Kinase IIProtein Kinase InhibitorsAntiviral AgentsHalogenationHumansAnimalsBiological AvailabilityAdministration, OralPyrimidinesStructure-Activity RelationshipSARS-CoV-2

Stichwörter der Autor:innen

CSNK2SARS-CoV-2antiviralfluorinationpyrazolo[1,5-a]pyrimidineβ-coronavirus

Substanzen

Casein Kinase IIProtein Kinase InhibitorsAntiviral AgentsPyrimidines

Autor:innen und Institutionen

  • Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, NC 27599, USA.
  • Structural Genomics Consortium (SGC) and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

ORCID-Profile: Han Wee Ong, Jeffery L Smith, Rafael M Couñago, Edcon Chang, Andreas Krämer, Alison D Axtman, David H Drewry, Timothy M Willson

Förderung

  • Department of Defense ALSRP award
  • Rapidly Emerging Antiviral Drug Development Initiative (READDI)
  • NIH HHS
  • Structural Genomics Consortium (SGC)
  • NIDDK NIH HHS
  • Millennium Pharmaceuticals (Takeda)
  • NIH Illuminating the Druggable Genome
  • NC Biotech Center Institutional support grant

Zitieren

APA

Ong, H. W., Yang, X., Smith, J. L., Taft-Benz, S., Howell, S., Dickmander, R. J., Havener, T. M., Sanders, M. K., Brown, J. W., Couñago, R. M., Chang, E., Krämer, A., Moorman, N. J., Heise, M., Axtman, A. D., Drewry, D. H., & Willson, T. M. (2024). Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2. Molecules. https://doi.org/10.3390/molecules29174158

Vancouver

Ong HW, Yang X, Smith JL, Taft-Benz S, Howell S, Dickmander RJ, et al. Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2. Molecules. 2024. doi:10.3390/molecules29174158

BibTeX
@article{Ong2024,
  author = {Ong, Han Wee and Yang, Xuan and Smith, Jeffery L and Taft-Benz, Sharon and Howell, Stefanie and Dickmander, Rebekah J and Havener, Tammy M and Sanders, Marcia K and Brown, Jason W and Couñago, Rafael M and Chang, Edcon and Krämer, Andreas and Moorman, Nathaniel J and Heise, Mark and Axtman, Alison D and Drewry, David H and Willson, Timothy M},
  title = {Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29174158}
}
Kostenlos starten →